Completed PHASE2 INTERVENTIONAL 3-arm NCT02583022

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

A Randomized, Open-label, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Atopic Dermatitis

Sponsor: Amorepacific Corporation

Conditions Atopic Dermatitis

Interventions Elidel cream 1% PAC-14028 cream 1.0% PAC-14028 cream vehicle

Updated 5 times since 2017 Last updated: Oct 20, 2015 Started: Jun 30, 2013 Primary completion: Jan 31, 2014 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by Amorepacific Corporation and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amorepacific Corporation

Data source: Amorepacific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.